HC Wainwright Weighs in on Scholar Rock Holding Co.’s FY2025 Earnings (NASDAQ:SRRK)

Scholar Rock Holding Co. (NASDAQ:SRRK) – Investment analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Scholar Rock in a note issued to investors on Monday, October 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($2.43) per share for the year, down from their previous estimate of ($2.15). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.39) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2026 earnings at ($2.43) EPS, FY2027 earnings at ($2.02) EPS and FY2028 earnings at ($1.77) EPS.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same quarter in the previous year, the company earned ($0.47) EPS.

A number of other analysts have also commented on SRRK. BMO Capital Markets lifted their target price on Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Wedbush increased their price objective on Scholar Rock from $27.00 to $37.00 and gave the company an “outperform” rating in a research report on Monday. Finally, JPMorgan Chase & Co. decreased their target price on Scholar Rock from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, October 3rd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $27.75.

Scholar Rock Trading Down 5.8 %

Shares of NASDAQ SRRK opened at $27.77 on Wednesday. The company has a market cap of $2.21 billion, a PE ratio of -13.29 and a beta of 0.82. Scholar Rock has a 52-week low of $6.48 and a 52-week high of $35.38. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04. The firm’s 50 day moving average price is $10.01 and its 200-day moving average price is $10.99.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, Director Srinivas Akkaraju sold 1,175,713 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the completion of the sale, the director now directly owns 5,612,896 shares in the company, valued at $164,177,208. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the transaction, the director now owns 5,612,896 shares in the company, valued at $164,177,208. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tracey Sacco sold 30,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $25.62, for a total transaction of $768,600.00. Following the sale, the insider now directly owns 49,285 shares of the company’s stock, valued at approximately $1,262,681.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,415,340 shares of company stock valued at $40,666,088. 26.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in Scholar Rock by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,321,471 shares of the company’s stock worth $156,444,000 after acquiring an additional 1,149,519 shares during the period. Redmile Group LLC raised its position in shares of Scholar Rock by 0.3% during the 1st quarter. Redmile Group LLC now owns 6,419,610 shares of the company’s stock valued at $114,012,000 after purchasing an additional 17,105 shares during the period. Vanguard Group Inc. lifted its stake in shares of Scholar Rock by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock valued at $52,739,000 after buying an additional 114,550 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Scholar Rock by 31.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,430,764 shares of the company’s stock worth $26,898,000 after buying an additional 342,690 shares during the period. Finally, Millennium Management LLC increased its stake in Scholar Rock by 159.2% in the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company’s stock worth $7,710,000 after buying an additional 568,512 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.